Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31525729 | 0.87 | ALOX15 (0.47) | MTNR1AALOX15ALOX12MAPT | |
| SCHEMBL24090453 | 0.87 | ALOX15 (0.47) | MTNR1AALOX15ALOX12MAPT | |
| SCHEMBL9082928 | 0.82 | MTNR1A (0.57) | MTNR1ATP53LMNAALOX15ALOX12 | |
| SCHEMBL16303414 | 0.82 | MTNR1A (0.57) | MTNR1ATP53LMNAALOX15ALOX12 | |
| Hydrochloric Acid SCHEMBL10780018 | 0.81 | MTNR1A (0.56) | MTNR1ATP53LMNAALOX15ALOX12 | |
| SCHEMBL8394382 | 0.80 | MTNR1A (0.69) | MTNR1ATP53LMNAALOX15ALOX12 | |
| SCHEMBL19750357 | 0.80 | MTNR1A (0.54) | MTNR1ATP53LMNAALOX15ALOX12 | |
| SCHEMBL8394385 | 0.80 | MTNR1A (0.69) | MTNR1ATP53LMNAALOX15ALOX12 | |
| SCHEMBL17888019 | 0.80 | MTNR1A (0.64) | MTNR1ATP53LMNAALOX15ALOX12 | |
| SCHEMBL8394384 | 0.80 | MTNR1A (0.69) | MTNR1ATP53LMNAALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850276-B2 | Bidentate-binding modulators of LRRK2 and JNK kinases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2016-06-30 | — | — | US | disclosed |
| WO-2014200682-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | LRRK2, PINK1, MAP2K3 | MTNR1A 1721/4885TP53 1723/4885LMNA 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.